Clinical Trial Update: A Study of E7389 Liposomal Formulation (E7389-LF) Plus Nivolumab in Participants With Solid Tumor [Phase 1, Phase 2]

View source ↗

Summary

This entry provides an update on a Phase 1/2 trial of E7389-LF (liposomal irinotecan) combined with nivolumab in participants with solid tumors, noting that the…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumor

Drugs mentioned

• E7389-LF (liposomal irinotecan)
• nivolumab (nivolumab)

Snippet

Sponsor: Eisai Co., Ltd. | Conditions: Solid Neoplasms | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING